THE EFFECT OF CO-PROCESSED EXCIPIENTS DURING FORMULATION AND EVALUATION OF PEDIARIC LEVETIRACETAM ORODISPERSIBLE TABLETS IN RATS

MAHMOUD H. TEAIMA; HUSSIEN MOHAMED AHMED EL MESSIRY; TASNEEM DAHI OSMAN; MOHAMED A. EL-NABARAWI; DOAA A. HELAL

doi:10.22159/ijap.2023v15i1.45298

Authors

MAHMOUD H. TEAIMA Department of Pharmaceutics and industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt https://orcid.org/0000-0002-7565-301X
HUSSIEN MOHAMED AHMED EL MESSIRY Pharmaceutics Department, Egyptian Drug Authority, Cairo, Egypt https://orcid.org/0000-0002-3517-2027
TASNEEM DAHI OSMAN Pharmaceutics Department, Egyptian Drug Authority, Cairo, Egypt
MOHAMED A. EL-NABARAWI Department of Pharmaceutics and industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt https://orcid.org/0000-0003-0070-1969
DOAA A. HELAL Department of Pharmaceutics, Faculty of Pharmacy, Fayoum University, Fayoum, Egypt https://orcid.org/0000-0002-1222-8112

DOI:

https://doi.org/10.22159/ijap.2023v15i1.45298

Keywords:

Epilepsy, Levetiracetam (LVT), ODT, Pharmaburst® 500, Direct compression

Abstract

Objective: The main aim of this research was to make cost-effective taste-masking oral pediatric orodispersible tablets (ODTs) of Levetiracetam as an antiepileptic drug (AED) using various co-processed excipients by direct compression method.

Methods: Eight kinds of ready-made co-processed excipients in addition to sucralose and menthol as a sweetener, were utilized. The weight variation, drug content, friability, in vitro disintegration, dissolution time, hardness, thickness, and pharmacokinetics of the produced ODTs were determined.

Results: The optimized formula (F5) containing Pharmaburst® 500 showed the shortest disintegration time (11.66 sec) and more than 98% of Levetiracetam within 10 min (Q10). The Pharmacokinetic study of this optimum formula (F5) in rats using an HPLC-UV detector showed 26.904±2.027 ng/ml as the Cmax and 101.935±0.894 h ng/ml as AUC compared to commercial Tiratam® solution 10.421±0.295ng/ml and 23.135±0.43 h ng/ml respectively.

Conclusion: Levetiracetam orally orodispersible tablets were successfully prepared with acceptable hardness, satisfactory taste, and rapid disintegration in the oral cavity avoiding first-pass metabolism to yield the desired rapid effect in facing epilepsy for patients who experience dysphagia like pediatric and geriatric. In addition to the unconsciousness of the epileptic patient followed the seizure attack.

Downloads

Download data is not yet available.

References

Pack AM. Epilepsy overview and revised classification of seizures and epilepsies. Continuum (Minneap Minn). 2019;25(2):306-21. doi: 10.1212/CON.0000000000000707, PMID 30921011.

Stein MA, Kanner AM. Management of newly diagnosed epilepsy: a practical guide to monotherapy. Drugs. 2009;69(2):199-222. doi: 10.2165/00003495-200969020-00005, PMID 19228076.

Sankaraneni R, Lachhwani D. Antiepileptic drugs-a review. Pediatr Ann. 2015;44(2):e36-42. doi: 10.3928/00904481-20150203-10.

Jain KK. An assessment of levetiracetam as an anti-epileptic drug. Expert Opin Investig Drugs. 2000;9(7):1611-24. doi: 10.1517/13543784.9.7.1611, PMID 11060765.

Laffleur F, Keckeis V. Advances in drug delivery systems: work in progress still needed? Int J Pharm. 2020;590:119912. doi: 10.1016/j.ijpharm.2020.119912.

Ansari KK, Sharma N. Formulation and evaluation of orodispersible tablets of lornoxicam. J Drug Delivery Ther. 2018;8(6):225-8. doi: 10.22270/jddt.v8i6.2058.

Dey P, Maiti S. Orodispersible tablets: A new trend in drug delivery. J Nat Sci Biol Med. 2010;1(1):2-5. doi: 10.4103/0976-9668.71663, PMID 22096326.

Conceicao J, Adeoye O, Cabral Marques H, Concheiro A, Alvarez Lorenzo C, Sousa Lobo JM. Orodispersible carbamazepine/hydroxypropyl-β-cyclodextrin tablets obtained by direct compression with five-in-one co-processed excipients. AAPS PharmSciTech. 2020;21(2):39. doi: 10.1208/s12249-019-1579-5, PMID 31897724.

Moutasim MY, El-Meshad AN, El-Nabarawi MA. A pharmaceutical study on lornoxicam fast disintegrating tablets: formulation and in vitro and in vivo evaluation. Drug Deliv Transl Res. 2017;7(3):450-9. doi: 10.1007/s13346-017-0367-6, PMID 28283842.

Moqbel HA, ElMeshad AN, El-Nabarawi MA. Comparative study of different approaches for the preparation of chlorzoxazone orodispersible tablets. Drug Dev Ind Pharm. 2017;43(5):742-50. doi: 10.1080/03639045.2016.1225753, PMID 27534668.

El-Nabarawi MA, Teaima MH, Hamid MMA, Shoman NA, Mohamed AI, El-Sahar A. Formulation, evaluation and antioxidant activity of caffeine fast melt tablets. Res J Pharm Technol. 2018;11(7):3131-8. doi: 10.5958/0974-360X.2018.00575.9.

Donauer N, Lobenberg R. A mini-review of scientific and pharmacopeial requirements for the disintegration test. Int J Pharm. 2007;345(1-2):2-8. doi: 10.1016/j.ijpharm.2007.08.045, PMID 17935916.

Stoltenberg I, Breitkreutz J. Orally disintegrating mini-tablets (ODMTs)–a novel solid oral dosage form for paediatric use. Eur J Pharm Biopharm. 2011;78(3):462-9. doi: 10.1016/j.ejpb.2011.02.005, PMID 21324357.

Fouad SA, Malaak FA, El-Nabarawi MA, Abu Zeid K. Development of orally disintegrating tablets containing solid dispersion of a poorly soluble drug for enhanced dissolution: In vitro optimization/in vivo evaluation. PLOS ONE. 2020;15(12):e0244646. doi: 10.1371/journal.pone.0244646, PMID 33382789.

Engelbrecht L, Grobler CJ, Rheeders M. A simple and cost-effective HPLC‐UV method for the detection of levetiracetam in plasma/serum of patients with epilepsy. Biomed Chromatogr. 2017;31(10):e3969. doi: 10.1002/bmc.3969, PMID 28294369.

Chaowalit M, Worawan S, Jirapornchai S, Apirak S, Krisana K. Preformulation and physical properties study of fast disintegrating tablets from Thai traditional formula. Int J Pharm Pharm Sci. 2014;6(4):0975-1491.

Widodo RT, Hassan A. Compression and mechanical properties of directly compressible pregelatinized sago starches. Powder Technol. 2015;269:15-21. doi: 10.1016/j.powtec.2014.08.039.

Validation of methodology for assay, pharmaceutical equivalence, and comparative dissolution profile for tablets containing amlodipine besylate. JAPS. 2019;9(11):93-100. doi: 10.7324/JAPS.2019.91112.

Pabari R, Ramtoola Z. Effect of a disintegration mechanism on wetting, water absorption, and disintegration time of orodispersible tablets. J Young Pharm. 2012;4(3):157-63. doi: 10.4103/0975-1483.100021, PMID 23112534.

Brniak W, Jachowicz R, Krupa A, Skorka T, Niwinski K. Evaluation of co-processed excipients used for direct compression of orally disintegrating tablets (ODT) using novel disintegration apparatus. Pharm Dev Technol. 2013;18(2):464-74. doi: 10.3109/10837450.2012.710238, PMID 22881600.

Abdelmonem R, Eltahan M, El-nabarawi M. Development and evaluation of taste masked oro-disintegrating tablets of itopride hcl using different co-processed excipients: pharmacokinetics study on rabbits. Int J App Pharm 2022;14(3):69-79. doi: 10.22159/ijap.2022v14i3.44398.

Chaerunisaa AY, Sriwidodo S, Abdassah M. Microcrystalline cellulose as pharmaceutical excipient. Pharmaceutical Formulation Design Recent Practices. 2019;1:1-21.